Gregory John Hollis
The COVID-19 epidemic caused by the SARS-CoV-2 virus has reached pandemic proportions and caused worldwide instability. With limited ICU beds and insufficient respiratory support, healthcare systems were unprepared to treat patients who progressed to a severe acute respiratory syndrome, the dire sort of the COVID-19 disease. Current antiviral candidates tested or approved for COVID-19 are compounds that are repositioned from other indications. Generally, drugs are often repositioned for the treatment of the SARSCoV-2 infection if they need evidence of in vitro inhibition against human coronaviruses (CoV). For instance , remdesivir, which was originally intended for treating Ebola, has been recently approved for the treatment of COVID-19 requiring hospitalization; the anti-malaria drug chloroquine is additionally being evaluated for COVID-19 treatment; the anti-HIV drug combination lopinavir-ritonavir is employed off-label in many lower-income countries against COVID-19. Antivirals, however, may come short in severely ill COVID-19 patients. The “novel” coronavirus disease 2019 (abbreviated “COVID-19”) is that the third coronavirus outbreak emerging during the past 20 years . This communicable disease , sustained by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has been recently declared a worldwide pandemic by the planet Health Organization.
English 
Spanish 
Chinese 
German 
French 
Japanese 
Portuguese 
Hindi